Document is current
Any future updates will be listed below
-
Authors
Shimizu, Akihiro https://orcid.org/0009-0009-5234-4845
Tsuboi, Nobuo
Ueda, Hiroyuki
Koike, Kentaro
Okabe, Masahiro
Yokote, Shinya
Sasaki, Takaya
Hirano, Keita
Kawamura, Tetsuya
Yokoo, Takashi
Suzuki, Yusuke
,
Suzuki, Yusuke
Yokoo, Takashi
Aoki, Ryosuke
Fujimoto, Shouichi
Fukao, Yusuke
Fukuda, Akihiro
Hashiguchi, Akinori
Hataya, Hiroshi
Honma, Shiko
Ichikawa, Daisuke
Ito, Takafumi
Joh, Kensuke
Katafuchi, Ritsuko
Kihara, Masao
Kikuchi, Masao
Matsuzaki, Keiichi
Miura, Kenichiro
Miyazaki, Yoichi
Moriyama, Takahito
Muta, Kumiko
Nakanishi, Koichi
Nakatani, Shinya
Nihei, Yoshihito
Nishikawa, Masako
Nishino, Tomoya
Sakaguchi, Ryoko
Sanada, Satoru
Shirai, Sayuri
Shimizu, Akira
Shibata, Takanori
Shima, Yuko
Suzuki, Hitoshi
Takahashi, Kazuo
Tomino, Yasuhiko
Urushihara, Maki
Yasuda, Takashi
Yasuda, Yoshinari
-
Funding
Funding for this research was provided by:
The Japan Agency for Medical Research and Development (JP19ek0109261)
A Grant-in-Aid for Progressive Renal Diseases Research, Research on Rare and Intractable Diseases, from the Ministry of Health
- License Information
-
More Information
Article History
Received: 6 October 2025
Accepted: 10 December 2025
First Online: 4 February 2026
Declarations
:
: Yusuke Suzuki has received consulting fees from Otsuka Pharmaceutical (Visterra), Novartis, Chinook Therapeutics, Argenx, BioCryst, Alexion Pharmaceuticals, Renalys, Alpine, and George Clinical, as well as honoraria from Kyowa Kirin, Novartis, Mitsubishi Tanabe, Otsuka Pharmaceutical, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, and Chinook Therapeutics.
: The Ethics Review Board of the Jikei University School of Medicine approved the study protocol (36-212[12321]). Written informed consent was obtained for primary data collection, and opt-out consent was utilized for this secondary analysis. The study was conducted in accordance with the Declaration of Helsinki.
